43 results
424B5
CRNX
Crinetics Pharmaceuticals Inc
13 Sep 23
Prospectus supplement for primary offering
5:19pm
, Ph.D., D.A.B.T., held key leadership roles in the discovery and development of ORILISSA (elagolix), a nonpeptide product candidate designed … for the treatment of endometriosis and uterine fibroids that received marketing approval from the FDA in July 2018. In addition, Dr. Madan held a key leadership
424B5
CRNX
Crinetics Pharmaceuticals Inc
11 Sep 23
Prospectus supplement for primary offering
4:09pm
., D.A.B.T., held key leadership roles in the discovery and development of ORILISSA (elagolix), a nonpeptide product candidate designed for the treatment … of endometriosis and uterine fibroids that received marketing approval from the FDA in July 2018. In addition, Dr. Madan held a key leadership role
8-K
EX-99.1
o1tku
14 Nov 22
Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
8:15am
424B5
dg14 u88q
12 Aug 22
Prospectus supplement for primary offering
8:31am
8-K
EX-99.1
t5lr1
12 May 22
Crinetics Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
4:40pm
424B5
n4snoc2l6n2dt
13 Apr 22
Prospectus supplement for primary offering
4:22pm
8-K
EX-99.1
ttaiaz9z0mqk0ihgh4d
30 Mar 22
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
4:05pm
8-K
EX-99.1
vod0ulvdpgr
14 Mar 22
Crinetics Pharmaceuticals Appoints Caren Deardorf to Board of Directors
9:01am
424B5
f4k88hfr
21 Oct 21
Prospectus supplement for primary offering
4:26pm
424B5
6tm ok2k3cbving97d2
20 Oct 21
Prospectus supplement for primary offering
4:15pm
8-K
EX-99.1
8zp kc1y9a27g
2 Sep 21
Crinetics Pharmaceuticals Expands Executive Team with Addition of Jeff Knight as Chief Operating Officer
5:00pm
8-K
3podra
2 Sep 21
Crinetics Pharmaceuticals Expands Executive Team with Addition of Jeff Knight as Chief Operating Officer
5:00pm
S-3ASR
vbal7
10 Aug 21
Automatic shelf registration
5:25pm